Human Telomerase Reverse Transcriptase-Transduced Human Cytotoxic T Cells Suppress the Growth of Human Melanoma in Immunodeficient Mice

Cancer Research

Volumn 64, Issue 6, 2004, Pages 2153-2161

  Verra, Natascha C V ^a   Jorritsma, Annelies ^a   Weijer, Kees ^a,b   Ruizendaal, Janneke J ^a,c   Voordouw, Arie ^a,b   Weder, Pauline ^a   Hooijberg, Erik ^a,c   Schumacher, Ton N M ^a   Haanen, John B A G ^a   Spits, Hergen ^a,b   Luiten, Rosalie M ^a,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MELAN A; TELOMERASE REVERSE TRANSCRIPTASE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INTERFERON PRODUCTION; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; DNA-BINDING PROTEINS; GENETIC VECTORS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFLUENZA A VIRUS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; NUCLEAR PROTEINS; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 12144287161     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1339     Document Type: Article

References (35)

1. Crowley NJ, Vervaert CE, Seigler HF. Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells. Cancer Res 1992;52:394-9.
2. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7:452-8.
3. Malkovska V, Cigel FK, Armstrong N, Storer BE, Hong R. Antilymphoma activity of human γ δ T-cells in mice with severe combined immune deficiency. Cancer Res 1992;52:5610-6.
4. Sabzevari H, Reisfeld RA. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice. Cancer Res 1993;53:4933-7.
5. Stenholm AC, Kirkin AF, Zeuthen J. In vivo eradication of an established human melanoma by an in vitro generated autologous cytotoxic T cell clone: a SCID mouse model. Int J Cancer 1998;77:476-80.
6. Yang S, Linette GP, Longerich S, Haluska FG. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J Immunol 2002;169:531-9.
7. Zeh, H. J B, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-94.
8. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99:3916-22.
9. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl J Med 1995;333:1038-44.
10. Riddell SR, Greenberg PD. T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev Med Virol 1997;7:181-92.
11. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13.
12. Figlin RA, Pierce WC, Kaboo R, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997;158:740-5.
13. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (Wash DC) 2002;298:850-4.
14. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99:16168-73.
15. Pawelec G, Adibzadeh M, Rehbein A, Hahnel K, Wagner W, Engel A. In vitro senescence models for human T lymphocytes. Vaccine 2000;18:1666-74.
16. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66.
17. Hooijberg E, Ruizendaal JJ, Snijders PJ, Kueter EW, Walboomers JM, Spits H. Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. J Immunol 2000;165:4239-45.
18. Luiten RM, Pene J, Yssel H, Spits H. Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T cell clones and confers resistance to oxidative stress-induced apoptosis. Blood 2003;101:4512-9.
19. Roth A, Yssel H, Pene J, et al. Telomerase levels control the life span of human T lymphocytes. Blood 2003;102:849-57.
20. Blackburn EH. Telomere states and cell fates. Nature (Lond) 2000;408:53-56.
21. Weng NP, Levine BL, June CH, Hodes RJ. Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med 1996;183:2471-9.
22. Harley CB. Telomerase is not an oncogene. Oncogene 2002;21:494-502.
23. Rufer N, Migliaccio M, Antonchuk J, Humphries RK, Roosnek E, Lansdorp PM. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 2001;98:597-603.
24. Schreurs M, Scholten KBJ, Kueter EWM, Ruizendaal JJ, Meijer CJLM, Hooijberg E. In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J Immunol 2003;71:2912-21.
25. Weijer K, Uittenbogaart CH, Voordouw A, et al. Intrathymic and extrathymic development of human plasmacytoid dendritic cell precursors in vivo. Blood 2002;99:2752-9.
26. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-230.
27. Heemskerk MH, Hooijberg E, Ruizendaal JJ, et al. Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells. Cell Immunol 1999;195:10-7.
28. Moss PA, Moots RJ, Rosenberg WM, et al. Extensive conservation of α and β chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. Proc Natl Acad Sci USA 1991;88:8987-90.
29. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998;160:1750-8.
30. Yssel H, De Vries JE, Koken M, Van Blitterswijk W, Spits H. Serum-free medium for generation and propagation of functional human cytotoxic and helper T cell clones. J Immunol Methods 1984;72:219-27.
31. Ortaldo JR, Bonnard GD, Herberman RB. Cytotoxic reactivity of human lymphocytes cultured in vitro. J Immunol 1977;119:1351-7.
32. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science (Wash DC)1996;274:94-6.
33. Contag PR, Olomu IN, Stevenson DK, Contag CH. Bioluminescent indicators in living mammals. Nat Med 1998;4:245-7.
34. Wagar EJ, Cromwell MA, Shultz LD, et al. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice. J Immunol 2000;165:518-27.
35. Abe J, Wakimoto H, Tsunoda R, et al. In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-γ by adenovirus-mediated genetic transduction. Biochem Biophys Res Commun 1996;218:164-70.